drugset
drugset / Trial / NCT02095626

Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation

NCT02095626 ↗

Phase 2 Completed 20 enrolled Apeptico Forschung und Entwicklung GmbH
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the effect of orally inhaled AP-301 on primary graft dysfunction after lung transplantation.

Timeline

Start
2013-06
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AP301 Unknown 87.6 mg Inhaled

Indications

No indication recorded.